K-911 (NCX 470) works by combining bimatoprost with nitric oxide to target two different fluid drainage pathways in the eye. If approved by April 2027, it could become a once-daily option for patients with open-angle glaucoma or ocular hypertension; a major upgrade for those tired of juggling multiple drops. Meanwhile, Ocugen has dosed its first patient in a Phase 3 trial for a gene therapy targeting geographic atrophy; the advanced, vision-stealing form of dry AMD. This isn’t just another trial; it’s a first-in-class approach that could change how we treat this currently untreatable condition. And in a surprising twist, a new survey reveals only 14% of menopausal women recognize dry eye as a symptom; even though 78% are shocked to learn it’s linked to hormonal shifts. Dry eye isn’t just about screens or AC; it can silently chip away at daily life; reading, driving, working. As diagnostics and treatments evolve, access remains a barrier. But with new policy statements from ASCRS pushing for better coverage and innovation, there’s hope the system might finally catch up to the science.